The days of surgical excision for any atypical lesion have been replaced by more nuanced decision making and individualized patient management. Current management of many of these lesions continues to be controversial in regard to observation with close surveillance versus the need for surgical excision of these lesions based on future risk or whether these lesions are precursor lesion.
The goal of this book is to provide a concise but comprehensive review of atypical breast proliferative lesions and their management complexities. New data about breast cancer, risk factors for breast cancer, pathological features unique to each entity, the characteristic findings on imaging, risk stratification for genetic testing, as well as the current evidence-based management of each of these breast lesions are discussed in full detail. Assessment tools for risk prediction of breast cancer are also highlighted as chapters run the gamut of current imaging modalities, as well as advanced screening options available for diagnosis and following these patients.
Atypical Breast Proliferative Lesions and Benign Breast Disease will undoubtedly become a valuable resource for nurse practitioners, physician assistants, breast and surgical oncology fellows, genetic counselors, geneticists, as well as other clinicians and surgeons who are referred and manage these complex breast patients. All chapters in this text are written by experts in the field who have research and clinical interest in each of these disease entities, and include the most up-to-date research and clinical information to enhance our understanding and treatment of patients.
This book will provide a comprehensive review of this field and will serve as a valuable resource for clinicians, general surgeons, breast surgeons and surgical oncologists, as well as researchers with an interest in the management of atypical breast lesions. The book will review new data about breast cancer, risk factors for breast cancer, pathological features unique to each entity, the characteristic findings on imaging, risk stratification for genetic testing, as well as the current evidence-based management of each of these breast lesions. Our text will provide assessment tools for risk prediction of breast cancer. We will provide data on thecurrent imaging modalities, as well as advanced screening options available for diagnosis and following these patients. Current management of many of these lesions continues to be controversial in regard to observation with close surveillance versus the need for surgical excision of these lesions based on future risk or whether these lesions are precursor lesion. For ductal carcinoma in-situ, the debate continues in regards to whether this disease entity is a precursor lesion that can be managed with observation or hormonal therapy, or is DCIS cancer and treated with lumpectomy and radiation. Several studies have been published where patients are managed with observation and treatment with hormonal therapy before surgical management. New trials have already begun accruing patients with low to intermediate grade DCIS where patients will be managed with observation versus hormonal therapy only. Management of DCIS continues to evolve and current management will be discussed
This text will provide a concise but comprehensive summary of the current management of patients with atypical breast proliferative lesions and some benign breast lesions and will help guided management of these patients. All chapters in this text will be written by experts in the field in each of these disease entities. They will all include the most up to date research and clinical information to enhance our understanding and treatment of patients.
Farin Amersi
fibroepithelial lesions radial scar Lobular carcinoma Ductal carcinoma LCIS surgical oncology